Outgoing Food and Drug Administration Commissioner Dr. Margaret Hamburg, in what was likely her final public address as commissioner last Friday, raised serious concerns about possible patient harm that could occur as the result of the 21st Century Cures Act now circulating on Capitol Hill.
Mount Sinai Hospital had been working closely with mobile application developer LifeMap Solutions since the New York City-based firm was launched last May. That closeness paid off when an unexpected opportunity arrived.
Add one more remarkable thing to the list of what man's best friend can do: diagnose cancer.
Kareo, a provider of cloud-based software and services for independent medical practices, has acquired DoctorBase, a patient communication platform.
While most healthcare stakeholders have slowed their spending on Washington lobbying, one sector has cranked up the pressure—the medical-device industry.
Geisinger's second century of innovation: Health system spreading best practices through new company
One hundred years ago, when Abigail Geisinger, the widow of an iron mining magnate, founded the 63-bed George F. Geisinger Memorial Hospital in Danville, Pa., she told the chief surgeon: “Make my hospital right; make it the best.”
Fourteen hospitals operated by Franklin, Tenn.-based Iasis Healthcare are under scrutiny in the yearslong nationwide investigation into the suspected overuse of implantable defibrillators.
Pack-a-day smokers in the federal health program now have access to low-dose CT scans for the early detection of lung cancer even as experts continue to debate whether the benefits are worth the cost and risk of false positives.
Getting big-ticket medical devices, drugs and procedures covered by Medicare is getting harder, according to a new analysis of national coverage decisions between 1999 and 2012. The CMS was about 20 times more likely to say no in the more recent years.
Public interest and media attention around the Food and Drug Administration's proposal to regulate laboratory-developed tests (LDTs) has gone from a slow burn to steady flame in recent weeks. That is a good thing.
Democrats on the House Energy & Commerce Committee have withdrawn support from legislation that would loosen regulatory requirements on a broad range of new healthcare technologies, sources close to the legislative discussions say.
The CMS will continue ordering some drug and device manufacturers to collect evidence on how well their technologies work before giving its final approval on reimbursement.